Human familial neurohypophyseal diabetes insipidus (FNDI) is an autosomal dominant endocrine disorder that presents in early childhood as excessive drinking and urination as a consequence of a progressive loss of secretion of vasopressin (VP) from posterior pituitary nerve terminals. Mutations in the VP gene have been implicated as the cause of FNDI, but the mechanisms by which these mutants manifest their pathology, and prevent the secretion of the co-expressed wild-type protein, are unknown. One hypothesis suggests that mutant precursors are toxic, and stop the synthesis of wild-type VP by killing expressing cells. Another hypothesis suggests that aberrant interactions between mutant and wild-type precursors might directly inhibit the elaboration or secretion of the products of the normal allele. We have tested these hypotheses using new animal models---transgenic rats that express an FNDI mutant VP gene that encodes a truncated precursor (Cys67stop). Cell-specific and inducible expression of the Cys67stop mutation in rat VP hypothalamic neurons does not result in cell death or atrophy. Rather, expression of the FNDI mutant causes a neuronal pathology characterized by distorted structures in the cell body that are labeled by antisera that recognize endoplasmic reticulum (ER) markers, and that accumulate both mutant and wild-type VP gene products. This is accompanied by an increase in the abundance of the mannose-6-phosphate receptor (MPR), a marker of endosome-lysosome activity. We suggest that FNDI in humans may be initiated, as in our transgenic rat model, by the trapping of wild-type VP gene products within an ER, which is targeted for lysosomal degradation by autophagy.
uring times of restricted fluid intake, mammals respond to increased plasma osmolality by reducing the renal excretion of water. Tubular reabsorption of water is controlled by circulating levels of the antidiuretic hormone vasopressin (VP) (1, 2) , which is synthesized as part of a precursor in the cell bodies of magnocellular hypothalamic neurons. After signal peptide removal and disulfide bond formation in the endoplasmic reticulum (ER), the precursor is sorted and packaged into secretory granules in the trans-Golgi network (TGN). Subsequent processing events proceed as the granules are transported down axons from the cell body to nerve terminals in the posterior pituitary (3) . Here, the mature peptides are stored until mobilized for secretion by electrical activities governed by physiological cues.
Human familial neurohypophyseal diabetes insipidus (FNDI) presents in childhood as excessive drinking and urination as a consequence of a progressive loss of VP secretion in response to osmotic challenge (4) . Mutations in the VP gene have been associated with FNDI (5-7). However, in contrast with the recessive Brattleboro mutation, a single nucleotide deletion in the rat VP gene (8) that manifests itself only in the homozygous state, human FNDI is a progressive disease caused by dominant mutations in the VP gene (9) . In families afflicted with the Cys67stop mutation (5), a C to A transition replaces a cysteine (Cys; TGC) at position 67 of the neurophysin (NP-II) moiety with a translation termination codon (TGA; Fig. 1c ). As this premature termination eliminates the Cterminus of NP-II, including 5 out of 14 Cys residues, and all of CPP (Figs. 1a and 1c), the conformation of the truncated precursor is likely to be grossly affected.
Cultured mouse neuroblastoma Neuro-2a cells, which have a functional regulated secretory pathway, have been transfected with mutant VP genes in order to test two hypotheses regarding the etiology of FNDI (12, 13) . The first hypothesis suggests that aberrantly folded mutant protein is toxic to the cell. In this case, elaboration of VP encoded by the wild-type gene might not be affected until the death of the cell (12) . The second hypothesis suggests that heterodimerization of mutant with wild-type precursors might disrupt the elaboration of wild-type VP gene products (13) . In this case, elaboration of VP encoded by the wild-type gene would be directly inhibited by the expression of the mutant gene. Evidence suggests that both mechanisms may be operational, depending on the FNDI mutant tested (12, 13) . However, the physiological relevance of the Neuro-2a cell culture systems remains in doubt. It has been acknowledged (12) that an animal model of FNDI would reveal more about the etiology of this condition, especially with regard to aspects of hypothalamo-neurohypophyseal system development, morphology and function, and whole-animal physiology, that cannot be modeled in any other way. We have generated such a model by expressing the a Cys67stop FNDI mutant VP transgene in physiologically tractable rat hosts.
D MATERIALS AND METHODS

Transgenes
We have previously described transgenic rats bearing a rat VP transgene (5-VCAT-3) that shows an appropriate cell-specific and physiological expression (14, 15) . 5-VCAT-3 consists of the rat VP structural gene containing a chloramphenicol acetyl transferase (CAT) reporter sequence in exon III, flanked by 5 kb of upstream and 3 kb of downstream VP gene sequence. 5-VCAT-3 is expressed in VP, but not OT, magnocellular neurons, within which it is subject to dramatic up-regulation by osmotic stimuli (14, 15) . 5-VCAT-3 is also expressed ectopically in the heart and thymus (14) . A derivative of 5-VCAT-3, 3-VCAT-3 (Fig.1a) , is also expressed in magnocellular VP neurons (unpublished). Like 5-VCAT-3, transgene RNA levels dramatically increase after a chronic osmotic stimulus, but ectopic expression in the heart and thymus is less pronounced. Site-directed mutagenesis using PCR was used to make a derivative of 3-VCAT-3 that contains the Cys67stop mutation. Two oligonucleotides (the 5' 69-mer DMSL-25 corresponding to sequences in intron I of the rat VP gene which contain the restriction site SgrAI [GGT AAG TCT CTG AGA GAC TGC TGC ACA /CCG GTG ACA CAT CAG AGC TGA GGA GGT CCC CCA AGT GTT GTC] and the 3' 71-mer DMSL-24 corresponding to the intron II-exon II junction and containing the restriction site EspI and the Cys to STOP mutation TGC -> TGA [CCC CAT GCT CA/G CCC GCC TGG CTT TGT GCG CAC CAT CGC TGC AGC AGA TGC CCG CGG CAG CTC A/GC GGC CT] were used to introduce a single base pair mutation in residue 67 of the NP-II moiety. The 547 bp product derived from PCR amplification of 5-VCAT-323 was directly ligated into a pGEM-T plasmid (Invitrogen) and sequenced. The mutation introduced a new EspI site into the VP gene, located 50 bp upstream of the original Esp1. The 507 bp SgrA1-Esp1 fragment and the 40 residue EspI fragment were cloned into SgrAI and EspI cleaved 3-VCAT-3 to yield 3-VCAT-3-Cys67stop. The 3-VCAT-3-Cys67stop transgene fragment was excised from vector with EcoRI and purified for microinjection (16) .
Animals
Animals were cared for in accord with NIH guidelines and U.K. Home Office regulations. Transgenic rats were generated by microinjecting fertilized one-cell eggs obtained from Sprague-Dawley donors. All procedures have been described (16, 17) . Transgene copy number was determined by comparison of hybridization of a common probe to transgene and wild-type restriction fragments on a Southern blot. Line 3-VCAT-3-Cys67stop/1 has 6 copies of the transgene per haploid genome, whereas line 3-VCAT-3-Cys67stop/2 has 41. All data shown are from experiments performed on 3-VCAT-3-Cys67stop/2, but similar results were seen with 3-VCAT-3-Cys67stop/1. Dehydration of rats involved total fluid deprivation for up to 72 hr. Chronic intermittent dehydration (CID) involved 9 cycles of a 72 hr dehydration, followed by a 3-4 day period of recovery. After the ninth dehydration, animals were allowed access to water for 10 days to allow for full recovery, then dehydrated a further 72 hr and killed (termed "R+1").
Data on water intake and urine output were collected through each recovery period by housing the animals in metabolic cages (Harvard Bioscience). A one-way ANOVA at each time point was used to determine statistical significance. Brains were taken after 3-, 7-, 9-and "R+1" dehydration cycles. Non-transgenic littermates subjected to the same treatment were used as wild-type controls.
Northern blotting and in situ hybridization
Northern blotting and in situ hybridization of radiolabeled oligonucleotides to RNA in brain sections have been described (14, 15) . The oligonucleotide probe that specifically recognizes the transgene transcript corresponds to sequences within the CAT reporter (14, 15) .
Antisera
The mouse monoclonal antiserum PS41 (18) is directed against the C-terminal portion of NP-II (Figure 1c ), which is absent from the truncated Cys67stop. The mouse monoclonal antiserum PS60 specifically recognizes rat NP-I (18). The rabbit polyclonal antiserum 84-6 specifically recognizes rat NP-II (Ms. Sonia Birkett, Bristol Heart institute, unpublished observations). The HenryK antiserum recognizes rat NP-I and NP-II (19) . Rabbit anti-Cys67stop (CX67) serum was prepared by inoculation of rabbits with the peptide QKPCGSGGR, which corresponded to the predicted C-terminal sequence of the truncated VP precursor generated by the C to A mutation, with an additional N-terminal Cys residue to facilitate coupling to KLH. Secretory vesicles were identified using a mouse monoclonal anti-chromogranin A (Research Diagnostics Inc.). The mouse monoclonal antibody 1D3 (20) was raised against the distinct carboxy-terminal KDEL sequence of the mammalian, soluble resident endoplasmic reticulum (ER) protein, protein disulfide isomerase (PDI). 1D3 recognized PDI and calreticulin (another resident ER protein) in Western blots and labeled the ER by immunocytochemistry (20) . Mouse monoclonal anti-calnexin (Transduction Laboratories) recognizes residues 116-301 of human calnexin, an integral membrane protein located primarily in the ER. Lysosomal activity was assessed using a rabbit polyclonal antiserum (MPR; 21) raised against the bovine cation-independent mannose-6-phosphate receptor, a 300 kDa transmembrane glycoprotein that cycles along two pathways to deliver newly synthesized lysosomal hydrolases (bearing terminal mannose 6-phosphate residues) and extra-cellular lysosomal enzymes to pre-lysosomes. An increased anti-MPR immunoreactivity implies upregulated lysosomal activity. The non-lysosomal protein degradation machinery of the ubiquitin-proteasome pathway was investigated using a rabbit polyclonal antibody raised against bovine ubiquitin (DAKO).
Cell culture and transfection
The mouse neuroblastoma cell line Neuro-2a (ATCC CCL 131) was cultured in DMEM (Gibco BRL) supplemented with 4 mM glutamine, non-essential amino acids (Gibco BRL), 200 IU/ml penicillin, 200 µg/ml streptomycin and 10% FCS (Gibco BRL). Cells were transfected using calcium phosphate with plasmid expression vectors (pRc/RSV; Invitrogen) containing either the wild-type rat VP gene, or the Cys67stop mutated VP gene. Both structural genes were initially cloned as Pst I-Hind III fragments into the vector pSP72 (Promega). An Eco RI site was introduced 3' of the gene by the introduction of the Hind III-Xho I fragment of pRc/RSV (Invitrogen) and the genes was recloned as Eco RI-Eco RI fragments into pRc/RSV that had been completely digested with Eco RI, resulting in the loss of the transcription start site and polyadenylation signal of this vector. Thus, both the transcription start site and the polyadenylation signal in the resulting expression plasmids are provided by the VP genes. Stable clones were selected on medium supplemented with 600 µg/ml G418 (Gibco BRL). In some experiments, stable clones expressing either the wild-type or the Cys67stop mutation were transiently transfected with mutant or wild-type expression vectors, respectively.
Labeling of cells, immunoprecipitation, and gel-electrophoresis
Cells were cultured in 6-well plates, washed with phosphate-buffered saline and starved for 1 hr in DMEM without cysteine (DMEM without cysteine, methionine and glutamine (ICN), supplemented with 30 µg/ml methionine (Gibco BRL), glutamine, penicillin/streptomycin and 10% (v/v) FCS. Labeling was performed with 25 µCi 35S-cysteine (ICN) for the times indicated. For pulse-chase analysis, the chase was initiated by addition of ¼ volume of DMEM supplemented with 4 mM cold cysteine (ICN) and 10% (v/v) FCS. Cells were harvested by scraping and lysed in TX-100 lysis mix (50 mM Tris pH 7.4; 5 mM MgCl2; 0.5% (v/v) TX-100) for 0.5 hr on ice and nuclei were removed by centrifugation. NP-II-containing proteins were immunoprecipitated by addition of 1 µl HenryK antiserum. After 1 hr on ice, 20 µl of a 50% (w/v) suspension of protein A-Sepharose beads (Pharmacia) was added for another hour. Beads were recovered by centrifugation and washed four times with TX-100 washing buffer (50 mM Tris pH 7.4; 0.5% (v/v) TX-100; 150 mM NaCl; 5 mM EDTA). Immunoprecipitated protein was solubilized by boiling in SDS-sample buffer and separated by Tricine-SDS-PAGE on a 10%(w/v)/3% (w/v) gel. The MW-SDS-17S marker (Sigma) was used as a molecular weight marker. For the non-reducing gels the NP-II containing proteins migrated at an apparent molecular weight considerably smaller than their calculated weight. Protein gels were dried and radioactive bands were detected by analysis on a BAS1000 PhosphorImager (Fujix).
Immunohistochemistry
Tissue section
Rats were anesthetized and perfusion fixed with 50 ml phosphate-buffered saline (PBS) immediately, followed by 200 ml Bouin's fixative. Whole brains were dissected, trimmed and placed into pots of fresh fixative for 1-2 hr at 4ºC then transferred into 20-30% (w/v) sucrose/PBS at 4ºC until the brains were completely cryoprotected. 15 µm sections were collected and stored in PBS with 0.1% (w/v) sodium azide. Sections were washed twice in PBS for 10 min each time, pre-blocked in PBS/0.3% (v/v) Triton X-100/1% (w/v) BSA/0.2% (w/v) sodium azide (PBS-TBSa) for 30 min at room temperature, then incubated in primary antibody diluted in PBS-TBSa (rabbit polyclonals 1:500; mouse monoclonals 1:100) overnight at 4ºC. Sections were washed in PBS three times for 10 min each time, then incubated in Fluorescein or Texas Red conjugated anti-rabbit or antimouse secondary antibodies (Vector Laboratories) diluted in PBS (1:100) for 1 hr at room temperature in the dark, washed in PBS three times in the dark, then mounted in Vectashield (Vector Laboratories) for visualization by confocal microscopy.
Cells
Cells were grown on coverslips, differentiated by overnight culture in serum-free medium (N1 medium = DMEM supplemented with 3.222 mg/ml putrescine, 1.258 µg/ml progesterone, 1.038 µg/ml selenium, 12.5 µg/ml transferrin, 0.1 mg/ml BSA) supplemented with 5 µg/ml insulin), and fixation and immunofluorescence were performed as described (22) . Double immunofluorescence was performed with a 1:500 dilution of a rabbit polyclonal antiserum combined with a 1:100 dilution of a mouse monoclonal antiserum, followed by a 1:150 dilutions of the fluorescein-or Texas Redconjugated anti-rabbit or anti-mouse immunoglobulins (Vector Laboratories). Coverslips were mounted with DABCO/Mowiol and examined by confocal microscopy.
Confocal microscopy
Immunostained sections and cells were examined with a 16x (N.A. 0.5) and a 63x (N.A 1.32) planaplo objective on Leica DMRBE (Bristol) or DMIRB (Utrecht) fluorescence microscopes interfaced with a Leica TCS-NT (Bristol) or TCS4D (Utrecht) confocal laser scanning microscope equipped with a Kr/Ar mixed gas laser. Some images were zoomed using Leica TCS-NT software. Images were obtained using parameters to optimize resolution and with standard fluorescein and rhodamine filters (excitation 488 and 568 nm, respectively). Because the neuronal fibers and the cell bodies were in different focal planes, 8 sections were recorded for each cell and these 8 sections were projected to show both the cell body and the processes in the final picture.
Apoptosis
TdT-mediated dUTP nick end labeling (TUNEL; 23) was used to examine apoptosis in hypothalami of transgenic rats (In Situ Cell Death Detection Kit; Boehringer Mannheim). Frozen tissue sections (15 µm) were fixed in 4% (w/v) paraformaldehyde in PBS, pH 7.4 for 30 min at room temperature, rinsed in PBS, blocked in 0.3% H2O2 in methanol for 30 min at room temperature, washed in PBS and incubated in permeabilization solution (0.1% (v/v) Triton X-100 in 0.1% (w/v) sodium citrate) for 2 min on ice and rinsed twice in PBS. Sections were then incubated with 50 µl of TUNEL reaction mixture (using fluorescein-dUTP to label DNA strand breaks) for 60 min at 37ºC in a humidified chamber, rinsed three times in PBS then visualized by fluorescence microscopy. A positive control comprised fixed, permeabilized tissue sections incubated with 1 mg/ml DNase I.
Electron microscopy
Tissues were processed for transmission electron microscopy (24) . Animals were perfused intracardially with 0.9% (w/v) NaCl, followed by 4% (w/v) paraformaldehyde in 0.1 M phosphate-buffered saline, with or without 0.5% (w/v) glutaraldehyde. The brain was removed, the hypothalamus cut out and further fixed by immersing in the fixative at 4ºC overnight. Tissue was rinsed and stored in 0.05 M Tris-buffered saline (TBS, pH 7.6). 50 µm sections of the hypothalamus were cut on a vibratome and the PVN and SON were dissected out. Tissue was subjected to a freeze-thaw pretreatment of incubations of 30 min in 5% (v/v) glycerol, 10% (w/v) sucrose, then 10% (v/v) glycerol, 15% (w/v) sucrose, both in 0.05 M TBS (pH7.6). After incubation with 10% (v/v) glycerol, 25% (w/v) sucrose overnight at 4 C, vials were snap frozen in liquid N2 and allowed to thaw. This was repeated before the tissue pieces were rinsed in 0.05M TBS (pH7.6). Tissue pieces were immunolabeled prior to processing for transmission electron microscopy by free floating incubation at 4ºC overnight in antisera diluted in 0.05M TBS (pH 7.6), 1% (w/v) BSA pH7.6 (CX67 at 1:500; 1D3 at 1: 1000; PS41 at 1:200). Secondary antibody incubations for the rabbit polyclonal primary antibodies used goatanti-rabbit IgG ("Akon"; Netherlands Institute for Brain Research, Amsterdam) diluted 1:100, for 1 h, then PAP (peroxidase-anti-peroxidase) diluted 1:1000 for 1 h. Mouse monoclonal primary antibodies were detected by incubation for 1 hr with biotinylated horse-anti-mouse Ig (Vector) diluted 1:200, followed by ABC (avidin-biotin-complex; Vector) diluted 1:800. Each antibody incubation was, followed by 4 rinses of 15 min in 0.05M TBS (pH 7.6). Tissue was then subjected to an additional fixation step of 2.5% (w/v) glutaraldehyde in 0.1M PBS (pH 7.6) for 30 min, followed by rinsing in 0.1M PBS (pH 7.6). Labeling was developed by incubating tissue pieces with 3,3' diamino benzidine tetrachloride (DAB, Sigma) at a concentration of 0.5 mg ml -1 in 0.05M TBS pH 7.6 with 0.005% (v/v) H2O2. For CX67 labeled tissue pieces, 0.1M imidazole was added to the reaction mixture to intensify the DAB staining. After the DAB incubation, tissue was postfixed in 0.1 M osmium tetroxide in 0.1M PBS for 30 min at 4 C in the dark. After a rinse in 0.1M PBS (pH 7.6), tissues were progressively dehydrated through increasing concentrations of ethanol and propylene oxide. During the 70% (v/v) ethanol dehydration step, tissue was contrasted en bloc by inclusion of 1% (w/v) uranyl acetate. After embedding in Epon resin (Fluka), 60-70 nm sections were cut on an ultramicrotome (Reichert-Jung), collected to formvar-coated, 200 mesh nickel grids, and viewed under the electron microscope (Philips CM10).
RESULTS
Transgene 3-VCAT-3-Cys67stop (Fig. 1c) was derived from 3-VCAT-3 (Fig. 1b) and microinjected into fertilized one-cell rat eggs. Note that the microinjection process leaves the endogenous VP gene unchanged, thus enabling the effect of mutant expression on the elaboration of wild-type gene products to be studied. Four independently derived transgenic lines were derived. Two lines failed to transmit the transgene; the two remaining lines (3-VCAT-3-Cys67stop/1 and 3-VCAT-3-Cys67stop/2) were analyzed further. In situ hybridization (Fig. 1d) revealed appropriate cell-specific expression of the transgene in hypothalamic magnocellular neurons of the supraoptic nucleus (SON) and paraventricular nucleus (PVN). Transgene transcript levels are dramatically induced by physiological stimulation: whereas robust expression was observed in animals that had been dehydrated for 3 days, transgene RNAs were barely detectable in control animals. Northern blotting failed to reveal expression in any other brain or peripheral tissue (data not shown). The transgene RNA is translated into a peptide that can be detected in SON and PVN cell bodies, but not processes, of dehydrated rats using a specific antibody that recognizes the unique exposed C-terminal epitope found in the truncated Cys67stop precursor (Fig. 1e ).
Rats were assessed for effects of transgene expression on water balance by the noninvasive measurement of fluid intake and urine production. These parameters were compared in euhydrated wild-type, 3-VCAT-3 and 3-VCAT-3-Cys67stop rats. No differences were observed (not shown, but see basal data in Fig. 1f ), probably because transgene expression is too low to elicit an effect. We therefore developed a protocol---chronic intermittent dehydration (CID)---that involved 9 cycles of complete fluid deprivation (72 hours), followed by rehydration (96 hours), which ensured sustained transgene induction. After the 6th CID cycle, the 3-VCAT-3-Cys67stop rats drink significantly more, and produce significantly more urine, than control animals (Fig 1f) , after which animals returned to normal.
We next examined disease progression in 3-VCAT-3-Cys67stop transgenic rats at the cellular level (Fig 2) . We found that long term dehydration resulted in changes in the relative expression of Cys67stop, NP-I and NP-II. In euhydrated rats, there is little expression of Cys67stop, and NP-I and NP-II are expressed in mutually exclusive neuronal sub-sets (25, 26) in both wild-type and transgenic rats. After 3 CID cycles, abundant Cys67stop-like immunoreactivity was evident in the cell bodies of neurons with NP-II expression in axons as well as the cell body. Cys67stop and NP-I, and NP-I and NP-II immunoreactivities were generally present in mutually exclusive neuronal groups. By the 7th CID cycle, there was considerably more colocalization. Particularly, all Cys67stop expressing cells also accumulated NP-I in their cell bodies. Unexpectedly, after 9 CID cycles, although robust NP-II expression was sustained, NP-I and Cys67stop were barely detectable. However, we saw no evidence of atrophy or apoptosis (using TUNEL; not shown). Indeed, after rehydration and a further 72 hours of dehydration, Cys67stop-like immunoreactivity returned to the SON.
We then asked about the fate of the Cys67stop precursor in both a Neuro-2a neuroblastoma cell culture model and in transgenic rats, and we asked whether expression of the mutant precursor affected the elaboration of the wild-type gene products. The mutant precursor is not processed. Expression of the wild-type VP prohormone in Neuro-2a cells results in the partition of the NP-like material between the cell and the medium (Fig. 3a(i), lanes 1 and 2) . Both the unprocessed prohormone (VP-NP-CPP) and the partially processed VP-NP were constitutively secreted. However, most of the completely processed NP was stored within the cell, suggesting that it had entered the regulated secretory pathway. For the Cys67stop mutant, a single product was immunoprecipitated (Fig. 3a(i), lanes 3 and 4) that migrated with an apparent molecular mass of 8.5 kDa, corresponding to the predicted mass of the truncated prohormone (8.3 kDa). No processing was observed. Secreted mutant prohormone was barely detectable after an 18 hr metabolic labeling; the vast majority was retained in the cell. A pulse-chase analysis revealed the kinetics of wild-type VP prohormone secretion and processing [ Fig.  3a (ii)], with a gradual appearance of processed forms, and their appearance in the media. However, the Cys67stop mutant precursor remains within the cell, where it is degraded.
We then compared the intracellular localization of mutant and wild-type proteins. In Neuro-2a cells stably expressing the wild-type VP gene, NP-II immunoreactivity accumulated in the tips of the processes (Fig. 3b) , and colocalized with chromogranin A, a secretory granule marker (data not shown). Similarly, in rats, the wild-type NP-II protein can be traced from its genesis in the cell body, down axonal tracts (Fig. 1e) , which course from the magnocellular PVN and SON via the zona interna of the median eminence to posterior pituitary nerve terminals. In contrast, in both Neuro-2a cells (Fig.  3b ) and in transgenic rats (Fig. 1e) , the unprocessed Cys67stop precursor was excluded from processes. In rats, Cys67stop-like immunoreactivity could not be detected in the posterior pituitary (data not shown). Rather, the precursor accumulated in the ER in both Neuro2a cells (Fig. 3b ) and transgenic rats (Fig. 4b) . In rats, two cellular phenotypes were evident (Fig 4b) . The first phenotype, reminiscent of Neuro-2a cells, was characterized by a diffuse ER staining that colocalized with Cys67stop-like immunoreactivity. The second phenotype, not seen in Neuros-2a cells, was distinguished by a swollen structure in the cell body that was packed with Cys67stop protein, and which labeled with antisera against ER markers (Fig. 4a, Fig. 4b ).
We then asked whether the elaboration of wild-type gene products was altered by the coexpression of the mutant gene. The wild-type VP gene was transfected into Neuro-2a cells stably expressing the Cys67stop prohormone [ Fig. 3c (i) ], and vice-versa [Fig 3c  (ii) ]. In neither case did co-expression of mutant and wild-type prohormones affect their relative subcellular locations. Similarly, expression of the Cys67stop mutant protein does not directly prevent the axonal localization of wild-type NP-II in transgenic rats (Fig. 3d) . However, after only one CID cycle, electron microscopy revealed sequestration not only of Cys67stop, but also of wild type NP-II (Fig. 5a ) in swollen structures in the cell body. After three CID cycles, these structures, which also labeled with antisera against ER markers (Fig. 5b) , appeared to be delimited by a membrane (Fig. 5b) . After 7 CID cycles, there is a marked increase in the abundance of the lysosomal marker MPR throughout the SON of transgenic, but not wild-type rats (Fig. 4c) , and this corresponds to the presence of NP-II-like immunoreactivity (Fig. 4d) . In contrast, the distribution and extent of ubiquitin staining in magnocellular neurons of transgenic rats brains did not differ from that of wild-type animals (not shown).
DISCUSSION
Any hypothesis that seeks to explain the etiology of FNDI must address its dominant and progressive nature. The two current hypotheses are not entirely consistent with clinical and experimental observations. The first hypothesis suggests that aberrantly folded mutant protein may be toxic to the cell (12) . In this case, elaboration of VP encoded by the wild-type prepropeptide might not be affected until the death of the cell, and this might explain the gradual onset of the disease. A limited number of autopsy studies have described atrophy of the hypothalamo-neurohypophyseal system in FNDI patients (27) but this is by no means a consistent observation (28) . Similarly, the characteristic posterior pituitary bright spot, revealed by magnetic resonance imaging of normal individuals, is absent in some FNDI patients, but normal in others (29) . Although reduced viability has been observed in cultured neuroblastoma cells transfected with FNDI mutants (13), we could find no evidence of atrophy or apoptosis in transgenic rats. Whereas neuronal atrophy might be a long term consequence in some cases of FNDI, it is probably not the primary cause of the disease. The second hypothesis suggests that heterodimerization of mutant with wild-type precursors might disrupt the elaboration of VP gene products (13) . However, this is difficult to reconcile with the progressive nature of the disease, and it has been shown that there is in fact little interaction between wildtype and Cys67stop precursors (13) . Indeed, in Neuro-2a cells co-transfected with Cys67stop mutant and wild-type VP transgenes, the latter continues to be delivered to granules in neurite extensions, and in Cys67stop transgenic rat magnocellular neurons, wild-type NP-II is still found in axons and in the posterior pituitary.
Magnocellular neurons expressing the Cys67stop transgene develop a subcellular pathology characterized by a grossly distorted ER that accumulates both mutant and wild-type NP-II. The ER serves as the primary sensor to integrate handling of nascent cargo with tissue and host physiology. The ability to recognize, retain and degrade misfolded, incompletely folded or partially assembled copies of the protein is called ER quality control. The Cys67stop protein is probably retained in the ER by a quality control mechanism that involves disulfide interchange interactions with matrix proteins (30) . Mutant Cys67stop possesses an unpaired Cys at residue 61 at the C-terminus of the mutant prohormone. In the wild-type prohormone, Cys 61 forms a disulfide bond with Cys 73 and is physically close to Cys 67 and Cys 85 in the crystal structure (31) . In the truncated prohormone, Cys 61 is likely to be exposed rather than buried in the folded molecule and is remotely placed from the other Cys residues N-terminal to it. It is not flanked by an acidic residue that may allow masking of the thiol (32) but by Phe and Gly in rats, and Ala and Gly in humans. Unless oxidized by an unknown mechanism, Cys 61 is eminently vulnerable to participation in disulfide interchange interactions with the protein matrix of the ER (32) . Thiol retention has also been postulated as the mechanism responsible for ER retention of ∆g227 FNDI mutant proteins, in which a single base deletion destroys the normal translation initiation codon of the VP prepropeptide (33) . Instead, translation is initiated at a downstream translation initiation codon, resulting in a truncated signal sequence that is functional, but not cleaved. The uncleaved signal sequence in this mutant may interfere with the disulfide pairing between the Cys residues in positions 1 and 6 of the hormone moiety, leaving these thiol groups potentially available for covalent interactions that ultimately result in the accumulation of disulfide linked aggregates in the ER. Preventing disulfide bond formation in VP by mutating one of its two Cys residues also caused ER retention and aggregation, even though the signal sequence was intact and correctly removed (33) .
Mutations that result in uneven numbers of Cys residues can also subject other proteins to thiol retention, altering their oligomerization status and function. It is possible that the Cys67stop protein may be involved in intermolecular disulfide bonding with other mutant VP prohormones presenting an exposed Cys 61, or even with wild-type prohormones at an intermediate folding stage when disulfide interchanges are reversible. Thus, whereas there is no evidence for specific interactions between wild-type and mutant NPs (13), non-specific disulfide interactions, leading to the formation of inappropriate non-selective aggregates, cannot be ruled out. Thus might the Cys67stop protein be responsible for the trapping of the wild-type VP precursor in the ER. Aggregate formation will be favored under conditions of high protein concentration in the confined microenvironment of the ER (34) . The high Cys content of NP-II would further favor intermolecular disulfide exchanges.
Proteins that have been retained in the ER are targeted for cytosolic degradation. Two major pathways are available: the autophagic lysosomal-endosomal pathway (35) , and the proteasome system (36) . Most substrates, including a majority of the ER retained proteins, are marked for proteasomal degradation by covalent linkage to multiple molecules of ubiquitin (37) . There is prominent ubiquitin staining in the SON of dehydrated wild-type and transgenic rats, but transgenesis does not alter the staining pattern. The mutant protein is thus probably selectively targeted to the normally functioning cytosolic proteasome system, leaving most of the wild-type protein intact and capable of being delivered through the secretory pathway.
In contrast to ER-proteasomal protein degradation, which is highly selective for unassembled protein chains, autophagy is a non-selective bulk process (35, 38) whereby whole regions of cytoplasm become enveloped to form closed vacuoles, from which the sequestered material is subsequently delivered to lysosomes for degradation. Autophagic vacuoles sequester peroxisomes, mitochondria, neurosecretory vesicles, ER, ribosomes and cytosolic matrix substance for degradation (35, 38, 39) . Sequestration is energy dependent and starts with the formation of double-membrane sheets possibly derived from the ribosome-free regions of the ER (38) or the Golgi cisternae (35) . Acidification of the autophagic vacuole is accomplished by acquisition or activation of an H+-ATPase, after which acid hydrolases are delivered, either by MPR mediated transfer from endosomes (38, 40) or fusion with pre-existing MPR deficient lysosomes (41) . After hydrolysis of the contents, the autophagic vacuole is transformed into a residual body (35) .
In rats, two ER phenotypes were evident. The first---reminiscent of that seen in Cys67stop transfected Neuro-2a cells---was characterized by a diffuse ER staining that colocalized with Cys67stop-like immunoreactivity. The second phenotype, not apparent in Neuro-2a cells, was distinguished by a swollen and distorted ER that was packed with Cys67stop protein and also contained endogenous VP and OT. Transmission electron microscopy studies revealed that this dramatically dilated ER were morphologically distinct structures separate from typical ER. Some of these bodies were delimited by a thick membrane and contained structurally intact ER and aggregates of mutant protein, and may represent pre-autophagic vesicles that are targeted for lysosomal degradation. These presumptive pre-autophagic vacuoles were extremely prominent in the perikaryon, in contrast to previous observations that localized lysosomal compartments to axons and nerve terminals (39, 42) and interpreted as resorption of excess secretory products (43) or as a general turnover of cell constituents (39) . The crucial difference is that earlier studies of autophagy in the hypothalamus only examined endogenous proteins that could leave the ER and Golgi normally, unlike the mutant Cys67stop peptide. We thus postulate that autophagy is activated in neurons as a late response to ER pathology in FNDI.
The increased number of cation-independent MPR-positive endosomal compartments apparent only in our chronically stimulated transgenic rats demonstrates a marked activation of the endosomal-lysosomal system in these neurons. In contrast, lysosomal populations in the wild-type rat SON have previously been reported to decrease after 5 days of dehydration (44). Presumably, in response to the release of neurosecretory material prompted by physiological demand, there is no need to degrade excess material. In view of the subcellular pathology presented in the transgenic animals and the absence of increased MPR immunoreactivity in the hypothalami of similarly treated wild-type animals, we suggest that the prominent lysosomal up-regulation correlates with an accelerated autophagy.
Based on our observations in transfected Neuro-2a cells and in a transgenic rat model, we propose a new hypothesis to explain how the expression of a mutant FNDI allele can cause the loss of hormone production in VP neurons that continue to express the wildtype gene. The mutant Cys67stop possesses an unpaired Cys residue that will result in capture in the ER, probably by the thiol-retention quality control system. The captive mutant protein is likely to be targeted to the cytosolic ubiquitin-proteasome system, leaving the wild-type protein intact and capable of being delivered through the secretory pathway. However, as mutant proteins accumulate in the ER, aggregates will form which will also contain wild-type molecules, trapped by aberrant disulfide-bond interactions with Cys67stop. This results in the development of a subcellular pathology characterized by a grossly distorted ER that accumulates both mutant and wild-type NP-II. We propose that under these circumstances, the selective degradation system cannot cope, and a more general degradation system---autophagy---is activated to remove the deranged ER. Wildtype prohormone will be eliminated when the deranged organelle is destroyed, resulting in VP-deficiency. a, Structure of the rat VP-OT genes and of the proteins they encode. The VP and OT genes are closely linked, tail-to-tail, in the rat genome, being separated by an intergenic region of 11 kbp that contains a LINE element in the rat (10) The VP gene encodes a prepropeptide consisting of, from the N-terminus, the signal peptide (SP), the VP nonapeptide itself, the disulfide-rich neurophysin (NP) moiety and finally, a 39 amino acid glycopeptide (copeptin; CPP). The OT gene encodes a precursor with a similar structure, except for the absence of CPP. OT-associated NP is referred to as NP-I, whereas VP-associated NP is known as NP-II. NPs are known to be involved in three types of noncovalent interaction---hormone binding, dimerization (which is greatly facilitated by hormone binding), and further aggregation; through these interactions, the NPs are thought to play a role in the sorting of the prohormone into the secretory granule from the trans-Golgi network (TGN), and in intragranular processing and storage of hormone (11) . CPP has no known function. The recognition sites of specific antisera (PS41 and PS60) are shown. b, Structure of 3-VCAT-3. Transgene 3-VCAT-3 consists of the rat VP structural gene containing a chloramphenicol acetyl transferase (CAT) reporter in exon III, flanked by 3 kbp of upstream and 3 kbp of downstream sequences. The transgene encodes a modified prepropeptide in which CPP is truncated, the C-terminal 26 amino acids being replaced with a novel epitope tag (DR-12-EK14,15). c, Structure of 3-VCAT-3-Cys67stop. Transgene 3-VCAT-3-Cys67stop was derived from 3-VCAT-3. A C to A transition replaces a Cys (TGC) at position 67 of NP-II with a translation termination codon (TGA). The recognition site of a specific antibody (CX67) that specifically recognizes the exposed C-terminus of the Cys67stop mutant protein is shown. d, Dark-field image of in situ hybridization analyses of transgene expression in 3-VCAT-3-Cys67stop transgenic rats. Coronal brain sections from euhydrated (Control) transgenic rats or rats dehydrated for 3 days (Dehydration) were probed with a labeled oligonucleotide that hybridizes to the CAT component of the transgene RNA. Little expression is observed in control animals. In contrast, robust expression is seen in PVN and SON of dehydrated rats. Adherence of probe to blood vessels is non-specific. e, Transgene RNA is translated into a peptide that accumulates in the cell bodies of hypothalamic magnocellular neurons. Coronal brain sections from 3-VCAT-3-Cys67stop rats that had been dehydrated for 3 days were incubated with antisera specific for the endogenous wild-type NP-II (PS41) or the transgene peptide Cys67stop (CX67). CX67 reveals abundant peptide in the neuronal cell bodies of both the SON and PVN. In contrast, NP-II -like immunoreactivity is found in axons and cell bodies. CX67 staining is barely detectable in euhydrated animals (see fig 2) . f, Transient and inducible FNDI in Cys67stop transgenic rats. Wild-type (WT; n=4) and 3-VCAT-3-Cys67stop transgenic
